AlzeCure Pharma (Stockholm: ALZCUR)

Last close As at 27/03/2024

5.10

−0.18 (−3.41%)

Market capitalisation

SEK268m

Edison Investment Research is terminating coverage on AlzeCure Pharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

 

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | edison tv

AlzeCure Pharma: Edison Open House Healthcare 2022

Healthcare | Update

AlzeCure Pharma — Evolving into a mid-stage biotech

Healthcare | Flash note

AlzeCure Pharma — ACD856: Phase I progressing after SAD data

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 40.1 79.6 (32.4)
Relative 51.9 94.1 (9.4)
52 week high/low SEK7.6/SEK2.2

Financials

AlzeCure Pharma is a clinical-stage biotech company based in Sweden focused on developing innovative, small molecule drugs for the treatment of Alzheimer’s disease (symptomatic as well as disease modifying) and pain (neuropathic and osteoarthritic).

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2020A 0.0 (71.1) (71.4) (189.0) N/A N/A
2021A 0.0 (77.4) (77.8) (206.0) N/A N/A
2022E 0.0 (81.5) (81.9) (185.0) N/A N/A
2023E 0.0 (85.3) (85.6) (169.0) N/A N/A

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free